BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38551584)

  • 1. IL-6-Driven Autocrine Lactate Promotes Immune Escape of Uveal Melanoma.
    Gong C; Yang M; Long H; Liu X; Xu Q; Qiao L; Dong H; Liu Y; Li S
    Invest Ophthalmol Vis Sci; 2024 Mar; 65(3):37. PubMed ID: 38551584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
    Singh L; Singh MK; Kenney MC; Jager MJ; Rizvi MA; Meel R; Lomi N; Bakhshi S; Sen S; Kashyap S
    Cancer Immunol Immunother; 2021 May; 70(5):1291-1303. PubMed ID: 33136179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
    Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
    Feng J; Yang H; Zhang Y; Wei H; Zhu Z; Zhu B; Yang M; Cao W; Wang L; Wu Z
    Oncogene; 2017 Oct; 36(42):5829-5839. PubMed ID: 28604752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma.
    Benhassine M; Le-Bel G; Guérin SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormally expressed JunB transactivated by IL-6/STAT3 signaling promotes uveal melanoma aggressiveness via epithelial-mesenchymal transition.
    Gong C; Shen J; Fang Z; Qiao L; Feng R; Lin X; Li S
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29899166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
    de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
    J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
    Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
    Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
    J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of indoleamine 2,3-dioxygenase 1 expression in uveal melanoma.
    Liang C; Peng L; Zeng S; Zhao Q; Tang L; Jiang X; Zhang J; Yan N; Chen Y
    Exp Eye Res; 2019 Apr; 181():112-119. PubMed ID: 30639792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
    Zoroquiain P; Esposito E; Logan P; Aldrees S; Dias AB; Mansure JJ; Santapau D; Garcia C; Saornil MA; Belfort Neto R; Burnier MN
    Mod Pathol; 2018 Aug; 31(8):1201-1210. PubMed ID: 29581543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
    Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
    Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
    Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
    [No Abstract]   [Full Text] [Related]  

  • 15. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
    Javed A; Arguello D; Johnston C; Gatalica Z; Terai M; Weight RM; Orloff M; Mastrangelo MJ; Sato T
    Immunotherapy; 2017 Dec; 9(16):1323-1330. PubMed ID: 29185395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
    Tosi A; Cappellesso R; Dei Tos AP; Rossi V; Aliberti C; Pigozzo J; Fabozzi A; Sbaraglia M; Blandamura S; Del Bianco P; Chiarion-Sileni V; Rosato A
    J Exp Clin Cancer Res; 2021 May; 40(1):154. PubMed ID: 33947438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
    Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M
    PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.